Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date

Seres Therapeutics ( (MCRB) ) has shared an announcement.

Seres Therapeutics, Inc. announced that its 2026 annual meeting of stockholders is scheduled for June 9, 2026, with shareholders of record as of the close of business on April 13, 2026 entitled to vote. The company noted that, because this meeting will be held more than 30 days after the anniversary of the 2025 annual meeting, stockholder proposals under Rule 14a-8 must be received at its principal executive office by the close of business on March 26, 2026 to be eligible for inclusion in the 2026 proxy materials, signaling key procedural deadlines for investor participation in corporate governance.

The most recent analyst rating on (MCRB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Seres Therapeutics stock, see the MCRB Stock Forecast page.

Spark’s Take on MCRB Stock

According to Spark, TipRanks’ AI Analyst, MCRB is a Neutral.

The score is weighed down primarily by weak underlying financial performance (large ongoing operating losses, leveraged balance sheet, and limited evidence that the 2025 cash-flow improvement is durable) and bearish technical trend signals. Offsetting factors include constructive earnings-call updates on SER-155 progress and some financial stabilization, but funding dependence and lack of income-oriented support limit the overall score.

To see Spark’s full report on MCRB stock, click here.

More about Seres Therapeutics

Seres Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of therapeutic products. The company’s primary business involves activities related to its publicly traded common stock, with corporate governance processes centered around annual meetings and shareholder participation.

Average Trading Volume: 69,952

Technical Sentiment Signal: Sell

Current Market Cap: $82.73M

Learn more about MCRB stock on TipRanks’ Stock Analysis page.